L3MBTL4 methylation is a sensitive marker of DNA-PK inhibitor in pancreatic cancer.

Yao Y, Li Y, Gao A, Zhu C, Wang R, Li Y, Su X, Zhang M, Guo M

Open source

DOI
10.37349/etat.2026.1002382
Published
2026
Container
Exploration of targeted anti-tumor therapy
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.37349/etat.2026.1002382,
  title = {L3MBTL4 methylation is a sensitive marker of DNA-PK inhibitor in pancreatic cancer.},
  author = {Yao Y and Li Y and Gao A and Zhu C and Wang R and Li Y and Su X and Zhang M and Guo M},
  year = {2026},
  journal = {Exploration of targeted anti-tumor therapy},
  doi = {10.37349/etat.2026.1002382},
  url = {https://doi.org/10.37349/etat.2026.1002382}
}

RIS

TY  - JOUR
TI  - L3MBTL4 methylation is a sensitive marker of DNA-PK inhibitor in pancreatic cancer.
AU  - Yao Y
AU  - Li Y
AU  - Gao A
AU  - Zhu C
AU  - Wang R
AU  - Li Y
AU  - Su X
AU  - Zhang M
AU  - Guo M
PY  - 2026
JO  - Exploration of targeted anti-tumor therapy
DO  - 10.37349/etat.2026.1002382
UR  - https://doi.org/10.37349/etat.2026.1002382
ER  - 

APA

Y, Y., Y, L., A, G., C, Z., R, W., Y, L., X, S., M, Z., & M, G. (2026). L3MBTL4 methylation is a sensitive marker of DNA-PK inhibitor in pancreatic cancer.. Exploration of targeted anti-tumor therapy. https://doi.org/10.37349/etat.2026.1002382

Source records